Glenmark Life Sciences Limited (IN:ALIVUS)
:ALIVUS
Want to see IN:ALIVUS full AI Analyst Report?
ALIVUS Stock Chart & Stats
₹920.80
-₹16.95(-1.62%)
At close: 4:00 PM EST
₹920.80
-₹16.95(-1.62%)
Day’s Range― - ―
52-Week Range₹830.00 - ₹1,224.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)7.13K
Market Cap
₹127.34B
Enterprise Value₹124.35B
Total Cash (Recent Filing)₹6.53B
Total Debt (Recent Filing)₹1.13B
Price to Earnings (P/E)18.7
Beta0.76
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.56%
Share Statistics
EPS (TTM)N/A
Shares Outstanding122,736,350
10 Day Avg. Volume3,315
30 Day Avg. Volume7,125
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.50
Price to Sales (P/S)5.34
P/FCF Ratio51.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)52.7
Revenue Forecast (FY)₹28.31B
Bulls Say, Bears Say
Bulls Say
Very Low Leverage And Strong Equity BaseA very low debt-to-equity ratio and an expanded equity base provide durable financial flexibility: the company can invest in capacity, absorb regulatory or demand shocks, and pursue M&A or buybacks without risking solvency. Healthy ROE (~20%) shows efficient capital use over time.
Sustained High Operating And Net MarginsConsistently high EBITDA and net margins indicate structural cost advantages or pricing power in API manufacturing. Durable margin levels support internal investment, cushion profitability through cyclical downturns, and enable competitive reinvestment in process and compliance capabilities.
Positive Free Cash Flow With Strong FY2025 GrowthMaterial positive free cash flow and strong year-over-year FCF growth enhance long-term self-funding capacity for capex, R&D, and debt reduction. Reliable cash generation underpins financial resilience and supports stable supplier and customer relationships in contract manufacturing.
Bears Say
Modest Recent Revenue GrowthSlower top-line expansion reduces the company’s ability to scale fixed-cost advantages and limits long-term earnings leverage. In a capital-intensive API business, modest revenue growth constrains margin expansion, limits market share gains, and increases reliance on margin maintenance to drive returns.
Inconsistent Cash ConversionOperating cash flow trailing net income and variable cash conversion indicate working-capital or timing dynamics that can undermine free cash flow predictability. For a business requiring ongoing plant investment and regulatory spend, inconsistent cash conversion raises execution and liquidity planning risk.
Historical Swing In LeveragePrior periods of much higher leverage suggest the capital structure has been materially altered and could revert if management pursues aggressive expansion or faces stress. Such volatility raises uncertainty about risk tolerance and the stability of financing strategy over multi-quarter horizons.
Glenmark Life Sciences Limited News
ALIVUS FAQ
What was Glenmark Life Sciences Limited’s price range in the past 12 months?
Glenmark Life Sciences Limited lowest stock price was ₹830.00 and its highest was ₹1224.00 in the past 12 months.
What is Glenmark Life Sciences Limited’s market cap?
Glenmark Life Sciences Limited’s market cap is ₹127.34B.
When is Glenmark Life Sciences Limited’s upcoming earnings report date?
Glenmark Life Sciences Limited’s upcoming earnings report date is Jul 31, 2026 which is in 88 days.
How were Glenmark Life Sciences Limited’s earnings last quarter?
Currently, no data Available
Is Glenmark Life Sciences Limited overvalued?
According to Wall Street analysts Glenmark Life Sciences Limited’s price is currently Overvalued.
Does Glenmark Life Sciences Limited pay dividends?
Glenmark Life Sciences Limited pays a Semiannually dividend of ₹22.5 which represents an annual dividend yield of 0.56%. See more information on Glenmark Life Sciences Limited dividends here
What is Glenmark Life Sciences Limited’s EPS estimate?
Glenmark Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Glenmark Life Sciences Limited have?
Glenmark Life Sciences Limited has 122,736,350 shares outstanding.
What happened to Glenmark Life Sciences Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Glenmark Life Sciences Limited?
Currently, no hedge funds are holding shares in IN:ALIVUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Glenmark Life Sciences Limited
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
Technical Analysis
Caplin Point Laboratories Limited
―
Granules India Limited
―
Marksans Pharma Limited
―
Sanofi India Limited
―
Shilpa Medicare Limited
―